Imigrane (Sumatriptan Succinate)

Sumatriptan, the active ingredient in Imigrane, binds selectively to serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve fibers. This action causes vasoconstriction of dilated intracranial vessels and blocks the release of pain‑triggering neuropeptides, interrupting migraine pain pathways.

The appropriate dose of Imigrane is determined by the prescribing clinician based on individual patient factors and current clinical guidelines. Healthcare professionals select the dose that best balances efficacy and safety for each patient.

Safety data for Imigrane during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by the treating physician.

To order Imigrane, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Imigrane, as a subcutaneous sumatriptan injection, offers faster onset of relief compared with many oral triptans, which must be absorbed through the gastrointestinal tract. It is particularly useful when rapid symptom control is needed or when oral administration is not feasible.

Imigrane should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from direct sunlight, moisture, and extreme temperature fluctuations to maintain stability.

Imigrane is given as a single subcutaneous injection, typically into the outer thigh or abdomen. The injection should be performed by a trained healthcare professional using aseptic technique, and the patient should be observed for any immediate adverse reactions.

Serious risks include cardiovascular events such as myocardial infarction or stroke, severe hypertension, serotonin syndrome when combined with other serotonergic drugs, and rare but life‑threatening allergic reactions like anaphylaxis. Patients should seek immediate medical attention if these symptoms occur.

Imigrane is contraindicated in patients with known hypersensitivity to sumatriptan or any formulation components, uncontrolled hypertension, recent myocardial infarction or stroke, severe coronary artery disease, and in those taking ergot alkaloids or other triptans concurrently.